Home / Business and Economy / Strides Pharma Profit Soars 54% in Q4
Strides Pharma Profit Soars 54% in Q4
18 May
Summary
- Net profit surged 54.45% to Rs 126.94 crore in March 2026 quarter.
- Quarterly sales increased by 11.18% to Rs 1323.47 crore.
- Full-year net profit declined significantly by 84.52%.

Strides Pharma Science announced a robust financial performance for the quarter ending March 2026. The company's net profit saw a significant surge of 54.45%, climbing to Rs 126.94 crore from Rs 82.19 crore in the same period the previous year.
This impressive profit growth was accompanied by a healthy increase in sales, which rose by 11.18% to Rs 1323.47 crore in the March 2026 quarter. The operating profit margin for the quarter stood at 18.11%.
However, the full fiscal year ending March 2026 presented a contrasting picture. Net profit for the year declined sharply by 84.52% to Rs 556.19 crore, compared to Rs 3593.46 crore in the previous fiscal year. Despite this, annual sales saw a modest increase of 6.43% to Rs 4858.68 crore.